

## ABSTRACTS BY SESSION - POSTER SESSIONS

- PO-G-0224**      **TRANSITIONAL CARE IN INFLAMMATORY BOWEL DISEASE – A SINGLE CENTRE EXPERIENCE**  
**Anat Yerushalmy-Feler<sup>1</sup>, Yulia Ron<sup>2</sup>, Ayala Nachum<sup>3</sup>, Shlomi Cohen<sup>1,4</sup>, Iris Dotan<sup>5</sup>**  
<sup>1</sup>Pediatric Gastroenterology unit, “Dana-Dwek” Children’s Hospital, <sup>2</sup>Department of Gastroenterology, <sup>3</sup>Health and medical Psychological service, Tel Aviv Sourasky Medical Center, <sup>4</sup>Sackler Faculty of Medicine, Tel Aviv University, <sup>5</sup>IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- 
- PO-G-0225**      **NEW BIOMARKERS IN INFLAMMATORY BOWEL DISEASE: THE ROLE OF HMGB1**  
**Ramona Inferrera<sup>1</sup>, Antonino Randazzo<sup>1</sup>, Simona Valenti<sup>1</sup>, Claudio Romano<sup>1</sup>**  
<sup>1</sup>Paediatric Department, University of Messina, Messina, Italy
- 
- PO-G-0226**      **APPLICABILITY OF COLON CAPSULE ENDOSCOPY (CCE) IN PAEDIATRIC CROHN’S DISEASE**  
**Salvatore Oliva<sup>1</sup>, Giovanni Di Nardo<sup>1</sup>, Fortunata Civitelli<sup>1</sup>, Emanuele Casciani<sup>1</sup>, Francesca Maccioni<sup>1</sup>, Paola Papoff<sup>1</sup>, Stefano Luciani<sup>1</sup>, Cesare Hassan<sup>2</sup>, Salvatore Cucchiara<sup>1</sup>, Stanley A Cohen<sup>3</sup>**  
<sup>1</sup>Sapienza University of Rome, <sup>2</sup>Digestive Endoscopy Unit, Catholic University, Rome, Italy, <sup>3</sup>Digestive Health Care, Children’s Healthcare of Atlanta, Atlanta, United States
- 
- PO-G-0227**      **FIRST OBSERVATIONS OF THE USE OF BIOSIMILAR INFLIXIMAB FOR TREATMENT OF ULCERATIVE COLITIS IN PAEDIATRIC POPULATION.**  
**Dorota Jarz bicka<sup>1</sup>, Anna Plocek<sup>2</sup>, Joanna Sieczkowska<sup>1</sup>, Ewa Toporowska-Kowalska<sup>2</sup>, Jarosław Kierku<sup>1</sup>**  
<sup>1</sup>The Children’s Memorial Health Institute, Warsaw, <sup>2</sup>Medical University of Łódź, Łódź, Poland
- 
- PO-G-0228**      **GOLIMUMAB IN PAEDIATRIC PATIENTS WITH CROHN’S DISEASE REFRACTORY TO PREVIOUS TUMOR NECROSIS FACTOR ANTIBODY**  
**Judith Pichler<sup>1</sup>, Wolf Huber<sup>1</sup>, Nima Memaran<sup>1</sup>, Bettina Bidmon-Fliegenschnee<sup>1</sup>**  
<sup>1</sup>University Clinic Vienna, Vienna, Austria
- 
- PO-G-0229**      **EXTRA-INTESTINAL MANIFESTATIONS ASSOCIATED WITH MUTATIONS IN THE IL-10 PATHWAY**  
**Intan Yeop<sup>1,2</sup>, Mona Bajaj-Elliott<sup>2</sup>, Fevronia Kiparissi<sup>1</sup>, Mamoun Elawad<sup>1</sup>**  
<sup>1</sup>Great Ormond Street Hospital, <sup>2</sup>UCL Institute of Child Health, London, United Kingdom
- 
- PO-G-0230**      **IMPACT OF CONCOMITANT IMMUNOMODULATOR USE ON FORMATION OF ANTIBODIES TO INFLIXIMAB IN PAEDIATRIC CROHN’S DISEASE**  
**Hannah Kansen<sup>1</sup>, Roderick Houwen<sup>1</sup>, Patrick van Rheenen<sup>2</sup>, Walter Tjon a Ten<sup>3</sup>, Hankje Escher<sup>4</sup>, Victorien Wolters<sup>1</sup>**  
<sup>1</sup>Wilhelmina Children’s Hospital, University Medical Center, Utrecht, <sup>2</sup>University Medical Center, Groningen, <sup>3</sup>Maxima Medical Centre, Veldhoven, <sup>4</sup>Sophia Children’s Hospital, Academic Medical Center, Rotterdam, Netherlands